Liposomal bupivacaine and novel local anesthetic formulations
Published by Elsevier Ltd..
Novel preparations allowing for the extended duration of action of local anesthetics have many clinically relevant benefits. With regard to this, the development of liposomal bupivacaine has the potential to significantly impact patient care by improving perioperative pain control. The unique liposomal bilayer that encapsulates bupivacaine allows for a sustained release of local anesthetic for up to 72 h after a single use and can significantly decrease postoperative opioid consumption. SABER-bupivacaine is another depot formulation that helps in sustained release of bupivacaine from an encapsulated bupivacaine in a biodegradable sucrose acetate isobutyrate biolayer. HTX-011 is an investigational extended-release local anesthetic formulation currently undergoing Phase 3 clinical trials. HTX-011 is composed of a bioerodible polymer with bupivacaine and low-dose meloxicam in which the polymer undergoes hydrolysis and allows for sustained release of bupivacaine and meloxicam for 3 days. The present investigation reviews pharmacologic considerations related to the formulation of liposomal bupivacaine, current FDA-approved indications for its use, and future extended-release local anesthetic formulations currently under investigation.
| Errataetall: |
ErratumIn: Best Pract Res Clin Anaesthesiol. 2021 Dec;35(4):E1-E2. - PMID 34801220 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical anaesthesiology - 33(2019), 4 vom: 17. Dez., Seite 425-432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prabhakar, Amit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 17.04.2020 Date Revised 21.11.2021 published: Print-Electronic ErratumIn: Best Pract Res Clin Anaesthesiol. 2021 Dec;35(4):E1-E2. - PMID 34801220 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bpa.2019.07.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303935561 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303935561 | ||
| 003 | DE-627 | ||
| 005 | 20231225113908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpa.2019.07.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1013.xml |
| 035 | |a (DE-627)NLM303935561 | ||
| 035 | |a (NLM)31791561 | ||
| 035 | |a (PII)S1521-6896(19)30056-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prabhakar, Amit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liposomal bupivacaine and novel local anesthetic formulations |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2020 | ||
| 500 | |a Date Revised 21.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Best Pract Res Clin Anaesthesiol. 2021 Dec;35(4):E1-E2. - PMID 34801220 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Ltd. | ||
| 520 | |a Novel preparations allowing for the extended duration of action of local anesthetics have many clinically relevant benefits. With regard to this, the development of liposomal bupivacaine has the potential to significantly impact patient care by improving perioperative pain control. The unique liposomal bilayer that encapsulates bupivacaine allows for a sustained release of local anesthetic for up to 72 h after a single use and can significantly decrease postoperative opioid consumption. SABER-bupivacaine is another depot formulation that helps in sustained release of bupivacaine from an encapsulated bupivacaine in a biodegradable sucrose acetate isobutyrate biolayer. HTX-011 is an investigational extended-release local anesthetic formulation currently undergoing Phase 3 clinical trials. HTX-011 is composed of a bioerodible polymer with bupivacaine and low-dose meloxicam in which the polymer undergoes hydrolysis and allows for sustained release of bupivacaine and meloxicam for 3 days. The present investigation reviews pharmacologic considerations related to the formulation of liposomal bupivacaine, current FDA-approved indications for its use, and future extended-release local anesthetic formulations currently under investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bupivacaine | |
| 650 | 4 | |a liposomes | |
| 650 | 4 | |a local anesthetic | |
| 650 | 4 | |a microspheres | |
| 650 | 4 | |a multimodal analgesia | |
| 650 | 4 | |a regional anesthesia | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Anesthetics, Local |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Bupivacaine |2 NLM | |
| 650 | 7 | |a Y8335394RO |2 NLM | |
| 700 | 1 | |a Ward, Ceressa T |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Sanford, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Fiza, Babar |e verfasserin |4 aut | |
| 700 | 1 | |a Moll, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Rachel J |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan Hall, O |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Urman, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical anaesthesiology |d 2002 |g 33(2019), 4 vom: 17. Dez., Seite 425-432 |w (DE-627)NLM122752538 |x 1878-1608 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2019 |g number:4 |g day:17 |g month:12 |g pages:425-432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bpa.2019.07.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2019 |e 4 |b 17 |c 12 |h 425-432 | ||